Munnerstadt

Researchers are evaluating bronchoscopic lung volume reduction using thermoablation as a treatment for patients with severe emphysema. This prospective, randomized, open-label clinical trial compares this interventional procedure to the usual conservative standard therapy guided by GOLD guidelines. The study aims to provide evidence supporting this procedure as an effective and safe treatment option to improve care for emphysema patients based on current medical knowledge. The treatment involves using the InterVapor® System, which applies heated water vapor to ablate targeted lung regions. This process triggers lung remodeling through inflammation and healing, reducing tissue and air volume in diseased lung areas. The resulting lung volume reduction is expected to improve lung function, exercise capacity, and quality of life by decompressing healthier lung segments and enhancing respiratory muscle efficiency. Participants will be monitored for changes in patient-reported disease-specific quality of life over 9 months. The study includes assessments such as pulmonary function tests, high-resolution CT scans, blood gas measurements, dyspnea scoring, and a 6-minute walk test. Researchers will also evaluate safety and treatment effects through follow-up visits, with total participation lasting at least 9 months to track outcomes and any adverse events.

Researchers are collecting real-world data on patients in Germany with non-squamous metastatic non-small cell lung cancer (NSQ mNSCLC), including large cell neuroendocrine carcinoma if considered similar to NSCLC. The study focuses on patients starting first-line treatment with tremelimumab and durvalumab combined with platinum-based chemotherapy (TDC) following approved guidelines. This research aims to understand how genetic mutations such as KRAS, STK11, KEAP1, and TP53, as well as protein expressions like TTF-1 and PD-L1, affect treatment outcomes in routine clinical practice. The study observes patients who are scheduled to begin treatment with TDC without altering their care, as it is a non-interventional study. Data is gathered prospectively from multiple centers to analyze the effectiveness of TDC, especially in patient subgroups with certain high-risk genetic alterations. No experimental treatments are administered as part of the study. Participants will be monitored over time to measure overall survival up to two years after treatment initiation. Researchers will collect information on patient genetics, tumor markers, treatment responses, and survival outcomes. The study also ensures safety by following approved treatment guidelines and requires informed consent. The aim is to gather detailed data to support better biomarker-guided treatment decisions for NSQ mNSCLC.